Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot (2023 to 2033)

The global progressive multifocal leukoencephalopathy treatment market is expected to garner a market value of US$ 1,320 million in 2023 and is expected to accumulate a market value of US$ 1,773.97 million by registering a CAGR of 3% in the forecast period 2023 to 2033. The market for progressive multifocal leukoencephalopathy treatment registered a CAGR of 2% in the historical period 2018 to 2022.

The progressive multifocal leukoencephalopathy treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The progressive multifocal leukoencephalopathy treatment market offers a range of products and services for its effective management and treatment such as corticosteroids, such as prednisone, antiviral medications, such as cidofovir, Immunoglobulin therapy, and immunomodulatory treatments, such as interferon.

Data Points Key Statistics
Expected Market Value (2023) US$ 1,320 million
Anticipated Forecast Value (2033) US$ 1,773.97 million
Projected Growth Rate (2023 to 2033) 3% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Progressive Multifocal Leukoencephalopathy Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for progressive multifocal leukoencephalopathy treatment reflected a value of 2% during the historical period, 2018 to 2022.

The market for Progressive Multifocal Leukoencephalopathy Treatment is gaining prominence as it is considered a rare, life-threatening brain disease caused by the JC virus. Furthermore, due to the rarity of the disease, there is ongoing research into developing new treatments for PML, expected to drive demand for these treatments.

The development of new PML treatments is a high priority for the medical community due to the devastating effects of the disease and the limited treatment options available. As more effective treatments become available, the market for PML treatment is likely to grow. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Progressive Multifocal Leukoencephalopathy Treatments is fuelling the market growth. Thus, the market for progressive multifocal leukoencephalopathy treatment is expected to register a CAGR of 3% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Progressive Multifocal Leukoencephalopathy Treatment Market?

Growing advancements in diagnostic and treatment options to push the market growth

The global market for progressive multifocal leukoencephalopathy treatment is primarily driven by the incidence of blood cancers, including multiple myeloma, the development of new and effective treatment options, advancements in treatment technologies and development of new diagnostic technologies and the availability of more effective treatments. According to the latest studies, PML occurs in approximately one in 200,000 people. As per the same report, each year, it is estimated that 4,000 people develop PML in the United States and Europe combined.

The growth of the progressive multifocal leukoencephalopathy treatment market is owed to the increasing prevalence of the condition owing to the increasing use of immunosuppressive drugs for autoimmune and other conditions. As a result, the players in the market are working on the development of new diagnostic tools and imaging techniques that are likely to improve the accuracy of Progressive Multifocal Leukoencephalopathy diagnosis.

For instance, in November 2021, Japan approved the world's first oncolytic virus-based immunotherapy called Teserpaturev, bringing new hope to individuals struggling with a malignant brain tumor known as GBM. Teserpaturev is a genetically engineered herpes simplex virus type 1 (HSV-1) that boasts a unique capability of not only killing the brain tumor cells it infects, but also those that have spread to other parts of the brain. This is achieved by activating a patient's own immune system to fight the tumor.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Progressive Multifocal Leukoencephalopathy Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by the challenging factors such as limited availability and high cost of advanced Progressive Multifocal Leukoencephalopathy Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Progressive Multifocal Leukoencephalopathy Treatment and the availability of diagnostic and therapeutic options.

Region-Wise Insights

How is the Progressive Multifocal Leukoencephalopathy Treatment Market Turning Out in the South and East Asia Region?

Improvement in healthcare spending propelling growth of the regional markets

The South and East Asia is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the progressive multifocal leukoencephalopathy treatment in the region.
South Asia is an emerging market due to the increase in point of care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Progressive Multifocal Leukoencephalopathy Treatment in North America?

Increasing Prevalence of Skin Conditions Shaping Landscape for Progressive Multifocal Leukoencephalopathy Treatment in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region along with the high healthcare expenditure and a large geriatric population.

The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, high level of healthcare expenditure and the high incidence of PML leading to a large patient population are some of the factors responsible for the growth of the market in the region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Indication, Which Segment is Likely to Account for a Significant Share?

Rising prevalence of HIV infection to push market growth

According to the studies, 38 million people worldwide are currently living with HIV or AIDS. The increasing incidence of HIV infection in many middle- and low-income countries is projected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.

Favorable reimbursement policies for both HIV and cancer treatment are expected to further drive the growth of the progressive multifocal leukoencephalopathy market over the forecast period.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies to take the lead and drive market growth

According to the FMI analysis, Hospital pharmacy accounts for the largest market share. The requirement for several hospital stays and visits during the progressive multifocal leukoencephalopathy treatment facilitates the growth of this segment. The majority of the serious venous diseases involving the brain are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Market Competition

Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.

  • In October 2022, Cellevolve Bio, Inc., a company focused on developing and commercializing cell therapies, announced that its Investigational New Drug (IND) application for CE-VST01-JC has been approved by the USA Food and Drug Administration (FDA). CE-VST01-JC is a JC Virus Specific T Cell Therapy that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML) and has received orphan drug designation from the FDA. The safety and effectiveness of CE-VST01-JC will be tested in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 study called ASCEND-JC. The study is expected to enroll up to 60 patients across the USA, Canada, and EU, with the first patient enrollment anticipated in the first half of 2023.
  • In June 2021, Teserpaturev received conditional and temporary marketing approval in Japan for the treatment of malignant glioma, based on the results of a Japanese phase 2 clinical trial in patients with GBM. The trial showed that 92% of patients who received Teserpaturev immunotherapy treatment were still alive after one year, which is significantly higher than the typical 15% one-year survival rate in this group of patients receiving standard late-stage brain tumor treatments.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1,320 million
Market Value in 2033 US$ 1,773.97 million
Growth Rate CAGR of 3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Treatment
  • Indication
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • NeoImmuneTech
  • Inhibikase Therapeutics
  • Neurimmune
  • Pfizer Inc.
  • GSK Plc
  • Sanofi S.A.
  • Gilead Sciences Inc.
  • Allergan Plc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
Customization Available Upon Request

Key Segments Profiled in the Progressive Multifocal Leukoencephalopathy Treatment Industry Survey

Treatment:

  • Anti-retroviral Therapy
  • Antiviral/Anti JCV
  • Other Symptomatic

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Indication:

  • HIV/AIDS
  • Organ Transplantation
  • Multiple Sclerosis
  • Hematologic Malignancies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at US$ 1,320 million.

How was the market’s historical performance?

The market rose at a 2% CAGR from 2018 to 2022.

What will be the growth rate until 2033?

Until 2033, the market will experience a 3% CAGR.

What will be the market value in 2033?

The market shall reach US$ 1,773.97 million in 2033.

What is North America's expected share in 2023?

North America is likely to generate 40% revenue in 2023.

Table of Content
1. Executive Summary | Progressive Multifocal Leukoencephalopathy Treatment Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
        5.3.1. Anti-retroviral Therapy
        5.3.2. Antiviral/Anti JCV
        5.3.3. Other Symptomatic
    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
        6.3.1. HIV/AIDS
        6.3.2. Organ Transplantation
        6.3.3. Multiple Sclerosis
        6.3.4. Hematologic Malignancies
    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. South Asia
        8.3.5. East Asia
        8.3.6. Oceania
        8.3.7. MEA
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        9.2.1. By Country
            9.2.1.1. The USA
            9.2.1.2. Canada
        9.2.2. By Treatment
        9.2.3. By Indication
        9.2.4. By Distribution Channel
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Treatment
        9.3.3. By Indication
        9.3.4. By Distribution Channel
    9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Treatment
        10.2.3. By Indication
        10.2.4. By Distribution Channel
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Treatment
        10.3.3. By Indication
        10.3.4. By Distribution Channel
    10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. United Kingdom
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Europe
        11.2.2. By Treatment
        11.2.3. By Indication
        11.2.4. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Treatment
        11.3.3. By Indication
        11.3.4. By Distribution Channel
    11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. India
            12.2.1.2. Malaysia
            12.2.1.3. Singapore
            12.2.1.4. Thailand
            12.2.1.5. Rest of South Asia
        12.2.2. By Treatment
        12.2.3. By Indication
        12.2.4. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Treatment
        12.3.3. By Indication
        12.3.4. By Distribution Channel
    12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. China
            13.2.1.2. Japan
            13.2.1.3. South Korea
        13.2.2. By Treatment
        13.2.3. By Indication
        13.2.4. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Treatment
        13.3.3. By Indication
        13.3.4. By Distribution Channel
    13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. Australia
            14.2.1.2. New Zealand
        14.2.2. By Treatment
        14.2.3. By Indication
        14.2.4. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Treatment
        14.3.3. By Indication
        14.3.4. By Distribution Channel
    14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of MEA
        15.2.2. By Treatment
        15.2.3. By Indication
        15.2.4. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Treatment
        15.3.3. By Indication
        15.3.4. By Distribution Channel
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2022
            16.1.2.1. By Treatment
            16.1.2.2. By Indication
            16.1.2.3. By Distribution Channel
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2022
            16.2.2.1. By Treatment
            16.2.2.2. By Indication
            16.2.2.3. By Distribution Channel
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2022
            16.3.2.1. By Treatment
            16.3.2.2. By Indication
            16.3.2.3. By Distribution Channel
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2022
            16.4.2.1. By Treatment
            16.4.2.2. By Indication
            16.4.2.3. By Distribution Channel
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2022
            16.5.2.1. By Treatment
            16.5.2.2. By Indication
            16.5.2.3. By Distribution Channel
    16.6. United Kingdom
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2022
            16.6.2.1. By Treatment
            16.6.2.2. By Indication
            16.6.2.3. By Distribution Channel
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2022
            16.7.2.1. By Treatment
            16.7.2.2. By Indication
            16.7.2.3. By Distribution Channel
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2022
            16.8.2.1. By Treatment
            16.8.2.2. By Indication
            16.8.2.3. By Distribution Channel
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2022
            16.9.2.1. By Treatment
            16.9.2.2. By Indication
            16.9.2.3. By Distribution Channel
    16.10. India
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2022
            16.10.2.1. By Treatment
            16.10.2.2. By Indication
            16.10.2.3. By Distribution Channel
    16.11. Malaysia
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2022
            16.11.2.1. By Treatment
            16.11.2.2. By Indication
            16.11.2.3. By Distribution Channel
    16.12. Singapore
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2022
            16.12.2.1. By Treatment
            16.12.2.2. By Indication
            16.12.2.3. By Distribution Channel
    16.13. Thailand
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2022
            16.13.2.1. By Treatment
            16.13.2.2. By Indication
            16.13.2.3. By Distribution Channel
    16.14. China
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2022
            16.14.2.1. By Treatment
            16.14.2.2. By Indication
            16.14.2.3. By Distribution Channel
    16.15. Japan
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2022
            16.15.2.1. By Treatment
            16.15.2.2. By Indication
            16.15.2.3. By Distribution Channel
    16.16. South Korea
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2022
            16.16.2.1. By Treatment
            16.16.2.2. By Indication
            16.16.2.3. By Distribution Channel
    16.17. Australia
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2022
            16.17.2.1. By Treatment
            16.17.2.2. By Indication
            16.17.2.3. By Distribution Channel
    16.18. New Zealand
        16.18.1. Pricing Analysis
        16.18.2. Market Share Analysis, 2022
            16.18.2.1. By Treatment
            16.18.2.2. By Indication
            16.18.2.3. By Distribution Channel
    16.19. GCC Countries
        16.19.1. Pricing Analysis
        16.19.2. Market Share Analysis, 2022
            16.19.2.1. By Treatment
            16.19.2.2. By Indication
            16.19.2.3. By Distribution Channel
    16.20. South Africa
        16.20.1. Pricing Analysis
        16.20.2. Market Share Analysis, 2022
            16.20.2.1. By Treatment
            16.20.2.2. By Indication
            16.20.2.3. By Distribution Channel
    16.21. Israel
        16.21.1. Pricing Analysis
        16.21.2. Market Share Analysis, 2022
            16.21.2.1. By Treatment
            16.21.2.2. By Indication
            16.21.2.3. By Distribution Channel
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Treatment
        17.3.3. By Indication
        17.3.4. By Distribution Channel
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. NeoImmuneTech
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. Inhibikase Therapeutics
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. Neurimmune
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. Pfizer, Inc.
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. GlaxoSmithKline Plc
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. Sanofi S.A.
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. Gilead Sciences, Inc.
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. Allergan Plc.
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. Novartis AG
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. F. Hoffman - La Roche Ltd.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
        18.1.11. AbbVie Inc.
            18.1.11.1. Overview
            18.1.11.2. Product Portfolio
            18.1.11.3. Profitability by Market Segments
            18.1.11.4. Sales Footprint
            18.1.11.5. Strategy Overview
                18.1.11.5.1. Marketing Strategy
        18.1.12. Bristol-Myers Squibb Company
            18.1.12.1. Overview
            18.1.12.2. Product Portfolio
            18.1.12.3. Profitability by Market Segments
            18.1.12.4. Sales Footprint
            18.1.12.5. Strategy Overview
                18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Recommendations

Healthcare

Neurodegenerative Disease Market

May 2024

REP-GB-1052

250 pages

Healthcare

Brain Imaging And Neuroimaging Market

July 2023

REP-GB-1841

319 pages

Healthcare

Antiviral Drugs Market

July 2023

REP-GB-1951

315 pages

Healthcare

Brain Monitoring Systems Market

January 2023

REP-GB-1259

333 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Progressive Multifocal Leukoencephalopathy Treatment Market

Schedule a Call